Wedbush Reiterates Outperform on Disc Medicine, Maintains $100 Price Target

Benzinga · 2d ago
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and maintains $100 price target.